Related Experiment Video

Updated: Nov 11, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.7K

Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data

Begum Yetis Sayin1, Wael Al Mahmeed2, Hany Ibrahim Ragy3

  • 1Department of Cardiology, Memorial Ankara Hospital, Ankara, Turkey. begumyts@yahoo.com.

Advances in Therapy
|March 27, 2021
PubMed

Insights

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) study found lower stroke and bleeding rates but higher mortality in Middle East patients with non-valvular atrial fibrillation (AF). Treatment patterns varied globally.

Area of Science:

  • Cardiology
  • Epidemiology
  • Pharmacology

Background:

  • Non-valvular atrial fibrillation (AF) poses significant stroke and bleeding risks.
  • Real-world data on treatment patterns and outcomes in diverse populations are crucial for optimizing patient care.
  • The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) was established to address these needs.

Purpose of the Study:

  • To analyze real-life treatment patterns and clinical outcomes of patients with newly diagnosed non-valvular AF.
  • To investigate bleeding and thromboembolic events, international normalized ratio fluctuations, and therapy compliance.
  • To specifically examine AF management and outcomes in Middle East populations compared to global data.

Main Methods:

  • The GARFIELD-AF registry enrolled 1660 patients with non-valvular AF across cohorts 3-5.
  • Data included baseline characteristics, antithrombotic treatment strategies, and 1-year clinical outcomes (stroke, systemic embolism, major bleeding, all-cause mortality).
  • Analysis compared Middle East patient data with the rest of the world.

Main Results:

  • Novel oral anticoagulant prescriptions increased over time in sequential cohorts.
  • Middle East populations showed higher antithrombotic treatment use, including antiplatelet therapy, compared to non-Middle East regions.
  • Appropriate use of Factor Xa inhibitors/direct thrombin inhibitors (DTIs) was lower in the Middle East (57.1%) versus globally (74.4%).

Conclusions:

  • Patients with non-valvular AF in the Middle East experienced lower rates of stroke and bleeding but higher all-cause mortality compared to global cohorts.
  • Treatment strategies and outcomes in the Middle East warrant further investigation to improve patient care.
  • This registry provides valuable insights into the global management of atrial fibrillation.
Abstract

Keywords:
Antithrombotic treatmentAtrial fibrillationOral anticoagulantsStroke

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.1K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.9K

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
153
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
113
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
95
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
113
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
102
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
82